Jasper Therapeutics Inc (JSPR)
23.80
-0.02
(-0.08%)
USD |
NASDAQ |
May 23, 16:00
23.80
0.00 (0.00%)
After-Hours: 20:00
Jasper Therapeutics SG&A Expense (Quarterly): 4.774M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 4.774M |
| December 31, 2023 | 3.89M |
| September 30, 2023 | 4.514M |
| June 30, 2023 | 4.53M |
| March 31, 2023 | 4.142M |
| December 31, 2022 | 4.465M |
| September 30, 2022 | 3.686M |
| June 30, 2022 | 3.828M |
| Date | Value |
|---|---|
| March 31, 2022 | 4.59M |
| December 31, 2021 | 3.425M |
| September 30, 2021 | 2.891M |
| June 30, 2021 | 3.262M |
| March 31, 2021 | 1.834M |
| December 31, 2020 | 1.311M |
| September 30, 2020 | 1.488M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.311M
Minimum
Dec 2020
4.774M
Maximum
Mar 2024
3.509M
Average
3.828M
Median
Jun 2022
SG&A Expense (Quarterly) Benchmarks
| NovaBay Pharmaceuticals Inc | 3.346M |
| Palatin Technologies Inc | 2.033M |
| iBio Inc | 2.722M |
| Theriva Biologics Inc | 1.933M |
| Oragenics Inc | 1.797M |